Clinical Trials
- Prostate Cancer
PRISM: Patient Experiences with PET Imaging in Prostate Cancer
- Brain, Spinal Cord & Nervous System
Imaging pancreatic beta-cells with PET neuroimaging agent 11C-PHNO
- Ages18 years - 65 years
- GenderBoth
- Thyroid and Other Endocrine Cancers, Pancreatic Cancer
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
- Stomach and Esophagus, Prostate Cancer, Bladder Cancer
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
- Phase 1 Cancers
PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours That Are MTAP Deficient
- Prostate Cancer, Bladder Cancer
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors
- Phase 1 Cancers
A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of Oral ATRN-119 In Patients With Advanced Solid Tumors
- Kidney Cancer, Head and Neck Cancers, Lung Cancer, Melanoma
XTX301 in Patients With Advanced Solid Tumors
- Phase 1 Cancers
A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-drug Conjugate DAY301 in Patients With Locally Advanced or Metastatic Solid Tumors
- Phase 1 Cancers
A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors